Abstract:Background We aimed to assess the value of induction chemotherapy with cisplatin and fluorouracil plus docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Methods We did an open-label phase 3 multicentre randomised controlled trial at ten institutions in China. Patients with stage III–IVB (except T3–4N0, UICC/AJCC 7th edition) NPC were randomly assigned to receive induction chemotherapy plus CCRT (investigational group) or CCRT alone (control group). Patients in both groups received cisplatin 100 mg/m2 every 3 weeks for three cycles, concurrently with intensity-modulated radiotherapy (IMRT). The investigational group received docetaxel (60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1), and fluorouracil (600 mg/m2 per day by continuous intravenous infusion on days 1–5) every 3 weeks for three cycles before CCRT. Our primary endpoint was failure-free survival (FFS), and the sample size was 476 patients (238 per treatment group). This trial is registered with ClinicalTrials.gov, NCT01245959. Findings 241 patients were assigned to the investigational group and 239 to the control group. After a median follow-up of 18.6 months (range 0.8–34 months), the estimated 2-year FFS was 82.2% in the investigational group and 75.5% in the control group (hazard ratio [HR] = 0.61, 95% confidence interval [CI] 0.39–0.97, p = 0.04). The estimated 2-year distant failure-free survival (D-FFS) was 91.3% in the investigational group and 81.7% in the control group (HR = 0.51, 95% CI 0.28–0.91, p = 0.02). No significant differences in overall survival and locoregional failure-free survival were observed between the two arms. The rates of grade 3–4 neutropenia, diarrhoea, and stomatitis during induction chemotherapy were 35.1%, 7.1%, and 6.3%, respectively. Interpretation The preliminary results suggested that compared with CCRT alone, induction chemotherapy with TPF could significantly improve FFS and D-FFS in locoregionally advanced NPC. Long-term follow-up is needed to establish an eventual efficacy of TPF induction chemotherapy. We aimed to assess the value of induction chemotherapy with cisplatin and fluorouracil plus docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). We did an open-label phase 3 multicentre randomised controlled trial at ten institutions in China. Patients with stage III–IVB (except T3–4N0, UICC/AJCC 7th edition) NPC were randomly assigned to receive induction chemotherapy plus CCRT (investigational group) or CCRT alone (control group). Patients in both groups received cisplatin 100 mg/m2 every 3 weeks for three cycles, concurrently with intensity-modulated radiotherapy (IMRT). The investigational group received docetaxel (60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1), and fluorouracil (600 mg/m2 per day by continuous intravenous infusion on days 1–5) every 3 weeks for three cycles before CCRT. Our primary endpoint was failure-free survival (FFS), and the sample size was 476 patients (238 per treatment group). This trial is registered with ClinicalTrials.gov, NCT01245959. 241 patients were assigned to the investigational group and 239 to the control group. After a median follow-up of 18.6 months (range 0.8–34 months), the estimated 2-year FFS was 82.2% in the investigational group and 75.5% in the control group (hazard ratio [HR] = 0.61, 95% confidence interval [CI] 0.39–0.97, p = 0.04). The estimated 2-year distant failure-free survival (D-FFS) was 91.3% in the investigational group and 81.7% in the control group (HR = 0.51, 95% CI 0.28–0.91, p = 0.02). No significant differences in overall survival and locoregional failure-free survival were observed between the two arms. The rates of grade 3–4 neutropenia, diarrhoea, and stomatitis during induction chemotherapy were 35.1%, 7.1%, and 6.3%, respectively. The preliminary results suggested that compared with CCRT alone, induction chemotherapy with TPF could significantly improve FFS and D-FFS in locoregionally advanced NPC. Long-term follow-up is needed to establish an eventual efficacy of TPF induction chemotherapy.

Preliminary Report of Randomized Phase Ii Clinical Study Comparing Standard Radiotherapy with or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (Npc)

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

Preliminary Results of a Phase III Randomized Study Comparing Chemotherapy Neoadjuvantly or Concurrently with Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study

[Chromosome X, poly-X].

Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy

Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma

Radiotherapy Alone Versus Concurrent Chemoradiotherapy in Intermediate Risk Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Noninferiority, Randomised Phase III Trial.

OP0010 Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: Preliminary results of a phase 3 multicentre randomised controlled trial

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma Interim Results from 2 Prospective Phase 2 Clinical Trials

Genetic variability in Melipona scutellaris from Recôncavo, Bahia, Brazil.

Concurrent Chemoradiotherapy With/without Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long‐term Results of Phase 3 Randomized Controlled Trial

A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer

Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial

An Open, Multicenter Clinical Study on Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Nasopharyngeal Carcinoma (npc): Preliminary Report

Testing the Effects of IT Tools on Firms' Innovation Capabilities